Head to Head Review: BioTelemetry (BEAT) vs. Cannabis Science (CBIS)

BioTelemetry (NASDAQ: BEAT) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Earnings & Valuation

This table compares BioTelemetry and Cannabis Science’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
BioTelemetry $208.33 million 3.93 $53.43 million $1.31 19.27
Cannabis Science N/A N/A N/A ($0.01) -3.87

BioTelemetry has higher revenue and earnings than Cannabis Science. Cannabis Science is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioTelemetry has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -4.04, suggesting that its share price is 504% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioTelemetry and Cannabis Science, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioTelemetry 1 0 7 0 2.75
Cannabis Science 0 0 0 0 N/A

BioTelemetry currently has a consensus price target of $43.50, suggesting a potential upside of 72.28%. Given BioTelemetry’s higher possible upside, equities research analysts clearly believe BioTelemetry is more favorable than Cannabis Science.

Profitability

This table compares BioTelemetry and Cannabis Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioTelemetry 16.10% 13.66% 8.44%
Cannabis Science -953,196.00% N/A -380.46%

Insider and Institutional Ownership

76.4% of BioTelemetry shares are held by institutional investors. 9.6% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioTelemetry beats Cannabis Science on 10 of the 10 factors compared between the two stocks.

About BioTelemetry

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

About Cannabis Science

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply